**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Alexander KOZAK, et al.

Serial No.: 09/856,009

Filed: May 16, 2001

Patent No.: 6,730,696 B1

Issued: May 4, 2004

For: **PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS**



Examiner: Sonia Wright (Art Unit: 1626)

Attn: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 22, 2005

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322(a)**

S I R:

In accordance with 37 C.F.R. §1.322(a)(1)(i), Applicants hereby request that the U.S. Patent and Trademark Office issue a Certificate of Correction for the above-identified U.S. patent correcting the claims as issued in this patent. Enclosed is Form PTO-1050 (four (4) sheets) showing the correction in this patent, namely, corrected claims 1, 2, 8, 9, 10 and 16. The error in not amending claims 1, 2, 8, 9, 10 and 16 prior to their issuance in this patent is an error that arose at the USPTO, as set forth below.

On October 7, 2003, the undersigned attorney for Applicants was contacted by the Examiner for this application, who indicated that she was prepared to allow the claims but with certain specified changes. On October 14, 2003, the undersigned attorney discussed this matter with the Examiner and reached an agreement with the Examiner as to the amendments of claims. On October 14, 2003, Applicants submitted an Amendment and Statement of Substance of Interview in order to implement the changes as discussed with the Examiner, wherein claims 1,

2, 10, 11, 12 and 20 of the application, which issued as claims 1, 2, 8, 9, 10 and 16 in the patent, were amended. On October 20, 2003, the USPTO Issued a Notice of Allowance for this application.

Attached hereto as Attachment A is a copy of the Amendment and Statement of Substance of Interview as transmitted to the USPTO by facsimile on October 14, 2003, along with copies of a Certificate of Transmission and the facsimile confirmation sheet showing that all pages were received by the USPTO. Attached hereto as Attachment B is a copy of a printout from the USPTO web site showing the transaction history for the prosecution of this patent application, which shows a Supplemental Response having been received by the USPTO on October 14, 2003. It is clear that the USPTO received a copy of the Amendment and Statement of Substance of Interview, wherein claims 1, 2, 8, 9, 10 and 16 of the patent were amended. However, the USPTO erroneously printed the patent without these amendments having been entered. Accordingly, a Certificate of Correction is now needed in order to ensure that claims 1, 2, 8, 9, 10 and 16 as amended are printed with this patent.

Because this error is the fault of the USPTO, no fee for issuance of a Certificate of Correction is due. If any fees are deemed to be due in connection with this Request, the Commissioner is authorized to charge payment to Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: _____
Morey B. Wildes
Reg. No. 36,968

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

CLIFFORD M. DAVIDSON
LESLYE B. DAVIDSON
CARY S. KAPPEL
WILLIAM C. GEHRIS
MOREY B. WILDES
ROBERT J. PARADISO
ERIK R. SWANSON***
THOMAS P. CANTY***

FELIX L. D'ARIENZO, JR.

DAVID G. KNASIAK
RICHARD V. ZANZALARI
BENJAMIN S. DIMARCO*
FRANKLIN S. ABRAMS
MICHELLE I. BLAT**
HEIDI M. STRUSE

INTELLECTUAL PROPERTY
NEW YORK | FRANKFURT

NEW YORK
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 SEVENTH AVENUE, 14TH FLOOR
NEW YORK, NY 10018
T. 212-736-1940
F. 212-736-2427
DDK@DDKPATENT.COM

FRANKFURT
DAVIDSON, DAVIDSON & KAPPEL EUROPE, LLC
ARNDTSTRASSE 11
60325 FRANKFURT AM MAIN, GERMANY
T. +49 (69) 788 088-0
F. +49 (69) 788 088-29
FRANKFURT@DDKPATENT.COM

*ADMITTED IN NEW JERSEY ONLY
**ADMITTED IN CONNECTICUT ONLY
***DDK EUROPE

# FACSIMILE TRANSMITTAL

FROM: Morey B. Wildes

DATE: October 14, 2003

OUR REF: 800.1012

NO. OF PAGES (including cover): 13

**PLEASE DELIVER THE FOLLOWING TO:**

| ***Recipients(s):*** | ***Fax Number:*** |
|---|---|
| Examiner Sonya Wright<br>U.S. Patent and Trademark Office<br>Group 1626 | (703) 746-3146 |

**MESSAGE:**



**IF THERE ARE ANY PROBLEMS WITH RECEPTION OF THIS FAX,
PLEASE CALL OR FAX SENDER TO ADVISE. THANK YOU.**

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


# TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

| | |
|---|---|
| Application Number | 09/856,009 |
| Filing Date | May 16, 2001 |
| First Named Inventor | KOZAk, et al. |
| Group Art Unit | 1626 |
| Examiner Name | Sonya N. Wright |
| Total Number of Pages in This Submission: 12 | Attorney Docket Number: 800.1012 |

**ENCLOSURES** ***(check all that apply)***

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☒ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☐ Other Enclosure(s) *(please identify below)*:

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

| | | | | | |
|---|---|---|---|---|---|
| *Name* | Davidson, Davidson & Kappel, LLC | | | | |
| *Address* | 485 Seventh Avenue, 14th Floor | | | | |
| *City* | New York | *State* | NY | *Zip Code* | 10018 |
| *Country* | USA | *Telephone* | (212) 736-1940 | *Fax* | (212) 736-2427 |

| | |
|---|---|
| Individual name | Morey B. Wildes |
| Signature |  |
| Date | October 14, 2003 |

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

| | | | |
|---|---|---|---|
| Typed or printed name | Morey B. Wildes | | |
| Signature |  | Date | October 14, 2003 |

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | | |
|---|---|---|
| Re: | Application of: | Alexander KOZAK, et al. |
| | Serial No.: | 09/856,009 |
| | Filed: | May 16, 2001 |
| | For: | **PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS** |
| | Examiner: | Sonya N. Wright |
| | Art Unit: | 1626 |

MAIL STOP: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 14, 2003

**AMENDMENT AND**
**STATEMENT OF SUBSTANCE OF INTERVIEW**

S I R:

In response to recent communications from and an interview by an attorney for Applicants with Examiner Sonya N. Wright in the U.S. Patent and Trademark Office in connection with the above-identified application, Applicants hereby amend this application as follows:

**Amendments to the Claims** are reflected in the listing of claims, which begins on page 2 of this paper.

**Remarks** begin on page 10 of this paper.

**IN THE CLAIMS:**

Please amend claims 1, 2, 10, 11, 12 and 20 as indicated below.

This listing of claims below will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of the general formula I




Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X- , wherein Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino and thio groups.

2. (Currently Amended) The compound according to claim 1, wherein the conjugated residue of ~~the nonsteroidal ant-inflammatory drug~~ indomethacin is pharmacologically inactive.

3. (Original) The compound according to claim 1, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

4. (Original) The compound according to claim 3, wherein said lipase is a phospholipase.

5. (Original) The compound according to claim 4, wherein said phospholipase is phospholipase $A_2$ ($PLA_2$).

6. (Original) The compound according to claim 1, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

7. (Original) The compound according to claim 1, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

8-9. (Canceled)

10. (Currently Amended) The compound according to claim 1 selected from the group consisting of:

~~1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,~~

1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl} sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine~~,~~

~~1-Stearoyl-2-{3-[α-methyl-4-(2-methylpropyl)benzeneacetamido] propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[α-methyl-4-(2-methylpropyl)benzeneacetamido] hexanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{3-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido] propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{4-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido] butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido] hexanoyl}-sn-glycero-3-phosphocholine, and~~

~~1-Stearoyl-2-{4-[2-(6-methoxynaphtyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine~~.

11. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I



Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;

R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;

D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X- , wherein Z is a saturated hydrocarbon chain having from 3 to 15 carbon atoms, and X is selected from amino and thio groups.

12. (Previously Amended) The pharmaceutical composition according to claim 11, wherein -C(O)-Z-X-D is an inactive derivative of ~~D~~ indomethacin.

13. (Original) The pharmaceutical composition according to claim 11, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

14. (Original) The pharmaceutical composition according to claim 13, wherein said lipase is a phospholipase.

15. (Original) The pharmaceutical composition according to claim 14, wherein said phospholipase is phospholipase $A_2$ ($PLA_2$).

16. (Original) The pharmaceutical composition according to claim 11, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

17. (Original) The pharmaceutical composition according to claim 11, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

18-19. (Canceled)

20. (Currently Amended) The pharmaceutical composition according to claim 11, wherein said compound of the general formula I is selected from the group consisting of:

~~1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,~~

1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido] propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine~~,~~

~~1-Stearoyl-2-{3-[α-methyl-4-(2-methylpropyl) benzeneacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[α-methyl-4-(2-methylpropyl)benzeneacetamido]-hexanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{3-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido]propanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{4-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido]-butanoyl}-sn-glycero-3-phosphocholine,~~

~~1-Stearoyl-2-{6-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido]-hexanoyl}-sn-glycero-3-phosphocholine, and~~

~~1-Stearoyl-2-{4-[2-(6-methoxynaphtyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine~~.

21. (Previously Amended) The pharmaceutical composition according to claim 11, in the form of solutions, suspensions, capsules, tablets, aerosols, gels, ointments or suppositories.

22. (Previously Amended) The pharmaceutical composition according to claim 11 for oral, ocular, nasal, parenteral, topical or rectal administration.

23. (Original) The pharmaceutical composition according to claim 22 for oral administration.

24. (Original) The pharmaceutical composition according to claim 22 for nasal administration.

25. (Previously Amended) The pharmaceutical composition according to claim 11 for the treatment of ~~a disease or disorder related to an~~ inflammato~~ry condition~~n.

26. (Original) The pharmaceutical composition according to claim ~~25~~ 11, wherein said

disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

27. (Canceled)

28. (Previously Amended) A method for treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 11.

29. (Original) The method according to claim 28, wherein said disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

30. (Previosuly Amended) A process for the synthesis of compounds of the general formula I as defined in claim 1, comprising:

(i) providing a molecule y-X-Z-COOH, wherein y is selected from H and OH, Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino, and thio groups;

(ii) replacing y with an appropriate blocking group, B, selected from the group consisting of benzyl chloromate, benzyloxycarbonate, diphenylcarbinol and trimethylacetamidocarbinol;

(iii) preparing an anhydride of the molecule B-X-Z-COOH by employing a reagent to remove one molecule of water from two protected bridging groups;

(iv) acylating a lyso-lecithin by the anhydride of step (iii) to yield 1-acyl-2-acyl(X-B)-sn-glycero-3 phospholipid by dissolving said anhydride and said lyso-lecithin in an organic solvent in the presence of a catalyst;

(v) removing the blocking group B from the functional group X; and

(vi) coupling a nonsteroidal anti-inflammatory drug D comprising indomethacin to the functional group X in an organic solvent in the presence of reagents that enable a condensation reaction wherein water molecules are removed, thus, generating a molecule of the general Formula I.

31. (Original) The process according to claim 30 wherein the protected functional group X is -NH.

32. (Original) The process according to claim 30 wherein the phospholipid of step (iv) is phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine.

33. (Canceled)

## REMARKS

Claims 1-7, 10-17, 20-26 and 28-32 are in this application, as previously amended by the Applicant in a Preliminary Amendment filed May 16, 2001, in a Supplemental Preliminary Amendment dated February 26, 2003 and in a Response to Office Action dated July 15, 2003.

On October 7, 2003, the undersigned attorney was contacted by the Examiner, who indicated that she was prepared to allow the claims but with certain changes. According to the Examiner, (1) claims 2 and 12 should be canceled, because the amendment of the definition of D in claims 1 and 11 have made these claims extraneous, and (2) the first six and last six compounds listed in claims 10 and 20 should be deleted, leaving only those middle five compounds with an indolyl group, because claims 1 and 11 have been limited to indomethacin.

On October 14, 2003, the undersigned attorney contacted the Examiner in reply and advised her that (1) claims 2 and 12 need not be canceled, because they are of different scope than their parent claims 1 and 11, although they are being amended to specifically recite indomethacin, as in the parent claims, and that (2) the first six and last six compounds listed in claims 10 and 20 may be deleted, leaving only those middle five compounds with an indolyl group. The undersigned attorney also advised the Examiner during this interview that the words "residue of" in the definition of D in claims 1 and 11 had inadvertently been deleted in the July 15, 2003 amendment.

The Examiner agreed with not canceling claims 2 and 12.

This amendment is being submitted in order to implement these enumerated changes, as discussed with the Examiner.

## Conclusion

Reconsideration of the present application, as amended, is requested. It is respectfully submitted that claims 1-7, 10-17, 20-26 and 28-32 remaining in this application are patentable.

If, upon review, the Examiner is unable to issue an immediate Notice of Allowance, the Examiner is respectfully requested to telephone Applicant's undersigned attorney in order to resolve any outstanding issues and advance the prosecution of the case.

An early and favorable action on the merits is earnestly solicited.

Respectfully Submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: _____
Morey B. Wildes
Reg. No. 36,968

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

* * * COMMUNICATION RESULT REPORT ( OCT. 14. 2003 3:53PM ) * * *

TTI DDK

TRANSMITTED/STORED OCT. 14. 2003 3:49PM

| FILE MODE | OPTION | ADDRESS | RESULT | PAGE |
|---|---|---|---|---|
| 8490 MEMORY TX | | 917037463146 | OK | 13/13 |

REASON FOR ERROR
E-1) HANG UP OR LINE FAIL
E-2) BUSY
E-3) NO ANSWER
E-4) NO FACSIMILE CONNECTION

CLIFFORD M. DAVIDSON
LESLYE B. DAVIDSON
CARY S. KAPPEL
WILLIAM C. GEHRIS
MOREY B. WILDES
ROBERT J. PARADISO
ERIK R. SWANSON***
THOMAS P. CANTY***

FELIX L. D'ARIENZO, JR.

DAVID G. KNASIAK
RICHARD V. ZANZALARI
BENJAMIN S. DIMARCO*
FRANKLIN S. ABRAMS
MICHELLE L. BLAT**
HEIDI M. STRUSE

INTELLECTUAL PROPERTY
NEW YORK | FRANKFURT

NEW YORK
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 SEVENTH AVENUE, 14TH FLOOR
NEW YORK, NY 10018
T. 212-736-1940
F. 212-736-2427
DDK@DDKPATENT.COM

FRANKFURT
DAVIDSON, DAVIDSON & KAPPEL EUROPE, LLC
ARNDTSTRASSE 11
60325 FRANKFURT AM MAIN, GERMANY
T. +49 (69) 788 088-0
F. +49 (69) 788 088-29
FRANKFURT@DDKPATENT.COM

*ADMITTED IN NEW JERSEY ONLY
**ADMITTED IN CONNECTICUT ONLY
***DDK EUROPE

# FACSIMILE TRANSMITTAL

FROM: Morey B. Wildes

DATE: October 14, 2003

OUR REF: 800.1012

NO. OF PAGES (including cover): 13

**PLEASE DELIVER THE FOLLOWING TO:**

| *Recipients(s):* | *Fax Number:* |
|---|---|
| Examiner Sonya Wright<br>U.S. Patent and Trademark Office<br>Group 1626 | (703) 746-3146 |

**MESSAGE:**



**IF THERE ARE ANY PROBLEMS WITH RECEPTION OF THIS FAX,
PLEASE CALL OR FAX SENDER TO ADVISE. THANK YOU.**

Printer Friendly

09/856,009 PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Transaction History

| Date | Contents Description |
|---|---|
| 05-04-2004 | Recordation of Patent Grant Mailed |
| 04-15-2004 | Issue Notification Mailed |
| 05-04-2004 | Patent Issue Date Used in PTA Calculation |
| 03-16-2004 | Receipt into Pubs |
| 03-11-2004 | Application Is Considered Ready for Issue |
| 01-08-2004 | Issue Fee Payment Verified |
| 05-16-2001 | Workflow - Drawings Finished |
| 03-02-2004 | Receipt into Pubs |
| 01-08-2004 | Issue Fee Payment Received |
| 12-12-2003 | Workflow - File Sent to Contractor |
| 10-20-2003 | Mail Notice of Allowance |
| 10-20-2003 | Mail Examiner's Amendment |
| 10-17-2003 | Notice of Allowance Data Verification Completed |
| 10-17-2003 | Case Docketed to Examiner in GAU |
| 10-17-2003 | Examiner's Amendment Communication |
| 10-17-2003 | Date Forwarded to Examiner |
| 10-14-2003 | Supplemental Response |
| 08-12-2003 | Date Forwarded to Examiner |
| 08-04-2003 | Supplemental Response |
| 08-01-2003 | Date Forwarded to Examiner |
| 07-17-2003 | Response after Non-Final Action |
| 04-15-2003 | Mail Non-Final Rejection |
| 04-07-2003 | Non-Final Rejection |
| 03-04-2003 | Preliminary Amendment |
| 02-26-2003 | Date Forwarded to Examiner |
| 02-11-2003 | Response to Election / Restriction Filed |
| 01-06-2003 | Mail Restriction Requirement |
| 01-06-2003 | Requirement for Restriction / Election |
| 11-21-2002 | Case Docketed to Examiner in GAU |
| 09-04-2001 | Information Disclosure Statement (IDS) Filed |
| 07-21-2001 | Case Docketed to Examiner in GAU |
| 05-16-2001 | Preliminary Amendment |
| 05-16-2001 | Request for Foreign Priority (Priority Papers May Be Included) |
| 07-10-2001 | Application Dispatched from OIPE |
| 07-06-2001 | IFW Scan & PACR Auto Security Review |
| 06-28-2001 | Correspondence Address Change |
| 06-25-2001 | Released to OIPE |
| 06-26-2001 | Notice of DO/EO Acceptance Mailed |
| 06-13-2001 | 371 Application Preexamination Docketing |
| 06-13-2001 | 371 Application Preexamination Docketing |
| 06-08-2001 | 371 Application Preexamination Docketing |
| 05-16-2001 | Receipt of 371 Request |
| 06-08-2001 | Correspondence Address Change |
| 05-16-2001 | Initial Exam Team nn |

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696



APPLICATION NO.: 09/856,009

ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In the claims, claims 1, 2, 8, 9, 10 and 16 should be replaced with the following amended claims 1, 2, 8, 9, 10 and 16:

1. A compound of the general formula I




Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;
R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;
D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X- , wherein Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino and thio groups.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696



APPLICATION NO.: 09/856,009

ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

(Continued)

2. The compound according to claim 1, wherein the conjugated residue of indomethacin is pharmacologically inactive.

8. The compound according to claim 1 selected from the group consisting of:
1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl} sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and
1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696



APPLICATION NO.: 09/856,009

ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

(Continued)

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I




Formula I

or a pharmaceutically acceptable salt thereof, wherein:

R1 is a saturated, substituted hydrocarbon chain having from 2 to 30 carbon atoms;
R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;
D is a residue of indomethacin, wherein D is attached through a functional group to a bridging group, -C(O)-Z-X- , wherein Z is a saturated hydrocarbon chain having from 3 to 15 carbon atoms, and X is selected from amino and thio groups.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 6,730,696



APPLICATION NO.: 09/856,009

ISSUE DATE : May 4, 2004

INVENTOR(S) : Alexander KOZAK, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

(Continued)

10. The pharmaceutical composition according to claim 9, wherein C(O)-Z-X-D is an inactive derivative of indomethacin.

16. The pharmaceutical composition according to claim 9, wherein said compound of the general formula I is selected from the group consisting of:

1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido] propanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,

1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and

1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Morey B. Wildes, Esq.
Davidson Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018